Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-02-22
2005-02-22
Canella, Karen A. (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C514S021800, C530S300000, C530S308000
Reexamination Certificate
active
06858576
ABSTRACT:
Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other anti-gastric emptying agents.
REFERENCES:
patent: 3862301 (1975-01-01), Chernish et al.
patent: 5187154 (1993-02-01), Phillips et al.
patent: 5264372 (1993-11-01), Beaumont et al.
patent: 5424286 (1995-06-01), Eng
patent: WO 9507098 (1995-03-01), None
patent: WO 9606628 (1996-03-01), None
patent: WO 9805351 (1998-02-01), None
patent: WO 9830231 (1998-07-01), None
patent: WO 9907404 (1999-02-01), None
Dupre, J. et al. Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes, 44: 626-630, Jun. 1995.*
Rai, A. et al. Actions of Helodermatidae venom peptides and mammalian glucagon-like peptides on gastric chief cells. Am. J. Physiol., 265 (gastrointest. Liver Physiol. 28): G118-G125, 1993.*
Daniel, O. et al. Use of glucagon in the treatment of acute diverticulitis. British Medical Journal, 3: 720-722, 1974.*
Vandermeeers et al, European Journal of Biochemistry, 1987, vol. 164, pp. 321-327.*
Strandberg et al (Acta Radiologica, 1988, vol. 29, pp. 49-52).*
GenBank Accession No. CAA24759, Feb. 9, 1999.*
Bayer et al., “Advances in Poison Management,”Clin. Chem.,42(8)(B):1361-66 (1996).
D'Alessio et al., “Glucagon-like Peptide 1 Enhances Glucose Tolerance Both by Stimulation of Insulin Release and by Increasing Insulin-independent Glucose Disposal,”J. Clin. Invest.,93:2263-66 (1994).
Holst, “Glucagonlike Peptide-1: A Newly Discovered Gastrointestinal Hormone,”Gastroenterology, 107:1848-55 (1994).
Lawler et al., “Comparison of Effects of Amylin, Glucagon-like Peptide-1 (GLP-1) and Exendin-4 to Inhibit Pentagastrin-Stimulated Gastric Acid Secretion in Rats,”Gastroenterology,112(4):A194, (1997).
Miholic et al., “Glucagon-like (GLP-1), Entleerung des Magenersatzes und das Dumpingsyndrom nach Gastrektomie,”Chirurgishes Forum,1991, pp. 429-432 (English abstract and International Search Report in which the article is referenced are attached).
Nauck et al., “Effects of Subcutaneous Glucagon-like Peptide 1 (GLP-1 [7-36 Amide]) in Patients with Type 2-Diabetes,”Diabetologia,Abstract A148, 38 Supp. 1:A39 (1995).
Orskov et al., “Is the Effect of Glucagon-like Peptide-1 on Gastric Emptying Centrally Mediated?”,Diabetologia,Abstract A147, 38 Supp. 1:A39, (1995).
Ritzel et al., “GLP-1 [7-36 Amide] Augments Bisphasic Insulin Secretion After Intravenous Glucose in Healthy Volunteers,”Diabetologia,Abstract A145, 38 Supp. 1:A39, (1995).
Navarro, M. et al., “Colocalization of Glucagon-Like Peptide-1 (GLP-1) Receptors, Glucose Transporter GLUT-2, and Glucokinase mRNAs in Rat Hypothalamic Cells: Evidence for a Role of GLP-1 Receptor Agonists as an Inhibitory Signal for Food and Water Intake,”Journal of Neurochemistry,67:1982-1991 (1996).
Daniel et al. “Use of Glucagon in the Treatment of Acute Diverticulitis,”Br. Med. J.,3:720, 1974.
D'Alessio et al. “Elimination of the Action of glucagon-like Peptide 1 Causes an Impairment of glucose tolerance after Nutrient Ingestion by Healthy Baboons,”J. Clin. Invest.,97:133-38, 1996.
Eissele et al. “Rat Gastric somatostatin and Gastrin Release: Interactions of Exendin-4 and Truncated Glucagon-Like Peptide-1 (GLP-1) Amide,”Life Sci.,55:629-34, 1994.
Eng et al. “Purification and Structure of Exendin-3, a New Pancreatic Secretagogue Isolated fromHeloderma horridumVenom,”J. Biol. Chem.,265:20259-62, 1990.
Eng et al. “Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, fromHeloderma suspectumVenom”,J. Biol. Chem.,267:7402-05, 1992.
Fehmann et al. “Stable Expression of the Rat GLP-1 Receptor in CHO Cells: Activation and Binding Characteristics Utilizing GLP-I(7-36)-Amide, Oxyntomodulin, Exendin-4, and Exendin(9-39),”Peptides15 (3): 453-6, 1994.
Ferguson et al. “Cell-Surface Anchoring of Proteins Via Glycosylphosphatidylinositol Structures”,Annu. Rev. Biochem.57:285-320, 1988.
Glauser et al. “Intravenous glucagon in the Management of Esophageal Food Obstruction”,J. Am. Coll. Emergency Physns,8:228, 1979.
Gedulin et al. “Comparison of Effects of Amylin, Glucagon-like Peptide-1 and Exendin-4 to Inhibit Pentagastrin-Stimulated Gastric Acid Secretion,”Diabetologia,40 (Suppl. 1):A300 (Abstract 1181) (1997) 8:228, 1979.
Goke et al. “Exendin-4 Is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulin-secreting β-Cells”,J. Biol. Chem.,268:19650-55, 1993.
Kolligs et al. “Reduction of the Incretin effect in Rats by the Glucagon-Like Peptide 1 Receptor antagonist Exendin(9-39) Amide”,Diabetes, 44:16-19, 1995.
Malhotra et al. “Exendin-4, a new peptide fromHeloderma suspectumvenom, potentiates cholecystokinin-induced amylase release from rat pancreatic acini”,Regulatory Peptides,41:149-56, 1992.
Montros-Rafizadeh et al. “Structure-function Analysis of Exendin-4 / GLP-1 Analogs”,Diabetes,45(Suppl. 2):152A, 1996.
O'Halloran et al. “Glucagon-like peptide-1 (7-36)-NH2: a physiological inhibitor of gastric acid secretion in man,”J Endocrinol126 (1): 169-73, 1990.
Orskov et al. “Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7-36 Amide and glucagonlike Peptide-1 7-37 in Healthy Subjects Are Indistinguishable”,Diabetes,42:658-61, 1993.
Raufman et al. “Truncated Glucagon-like Peptide-1 Interacts with Exendin Receptors in Dispersed Acini from Guinea Pig Pancreas”,J. Biol. Chem.267:21432-37, 1992.
Raufman et al. “Exendin-3, a Novel Peptide fromHeloderma horridumVenom, Interacts with Vasoactive Intestinal Peptide Receptors and a Newly Described Receptor on dispersed Acini from Guinea Pig Pancreas,”J. Biol. Chem.266:2897-902, 1991.
Scarpignato et al. “Action of Caerulein on gastric emptying of the Conscious Rat”,Arch. Int. Pharmacodyn. Ther.246:286-94 1980.
Schepp, et al. “Exendin-4 and exendin-(9-39)NH2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH2,”Eur. J. Pharm.269:183-91, 1994.
Schjoldager et al. “GLP-1 (Glucagon-like Peptide 1) and Truncated GLP-1, Fragments of Human Proglucagon, Inhibit Gastric Acid Secretion in Humans,”Dig. Dis Sci34 (5): 703-8, 1989.
Singh et al. “Use of125I-[Y39]exendin-4 to characterize exendin receptors on dispersed pancreatic acini and gastric chief cells from guinea pig,”Regul. Pept.53:47-59, 1994.
Stower et al. “A trial of glucagon in the treatment of painful biliary tract disease,”Br. J. Surg.,69:591-2, 1982.
Thorens et al. “Cloning and Functional Expression of the Human Islet GLP-1 Receptor,”Diabetes42 (11): 1678-82, 1993.
Thorens, “Expression cloning of the pancreatic β cell receptor for the gluco-incretin hormone glucagon-like peptide 1,”Proc. Natl. Acad. Sci. USA89:8641-45, 1992.
Wang et al. “Glucagon-like Peptide-1 Is a Physiological Incretin in Rat,”J. Clin. Invest.,95:417-21, 1995.
Wang, Y.J. and Hanson, M.A. “Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers,”Journal of Parenteral Science and Technology,Technical Report No. 10, Supp. 42:2S, 1988.
Wettergren et al. “Truncated GLP-1 (Proglucagon 78-107-Amide) Inhibits Gastric and Pancreatic Functions in Man,”Dig Dis Sci38 (4): 665-73, 1993.
Willms et al. “Gastric Emptying, Glucose Responses, and Insulin Secretio
Beeley Nigel Robert Arnold
Gedulin Bronislava
Prickett Kathryn S.
Young Andrew A.
Amylin Pharmaceuticals Inc.
Arnold & Porter LLP
Canella Karen A.
LandOfFree
Methods for regulating gastrointestinal motility does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for regulating gastrointestinal motility, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for regulating gastrointestinal motility will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3450837